Company Overview and News

5
Seadrill provides update on West Leo early termination litigation

2018-07-18 worldoil
LONDON -- Seadrill Partners LLC has announced that Tullow Ghana Limited will not be appealing the English High Court ruling in favor of Seadrill Ghana Operations Limited, relating to the early termination of the West Leo contract and Seadrill Ghana has received approximately $248 million, inclusive of interest, but net of withholding tax, VAT and legal expenses.
SDLP

51
[Press] SDRL - Seadrill Partners West Leo Early Termination Litigation Update

2018-07-18 oilvoice
Hamilton, Bermuda, July 18, 2018 - Seadrill Limited ("SDRL or the Company") announces today that a subsidiary of Seadrill Partners, the Master Limited Partnership it established in 2012 and in which it holds approximately a 46.6% interest in, has received approximately $248 million relating to the West Leo early termination litigation award.
SDLP SDRL

51
Seadrill Partners: Needs More Contracts

2018-07-16 seekingalpha
Seadrill Partners (NYSE:SDLP), amongst other offshore drillers, has seen their stock price being lifted, mostly as a result of the increase in the price of crude oil. We often see that investors want to make sure they enter a position early to try to maximize their profit, but this article will try to explain why it is too early to buy SDLP.
SDLP SDRL TLW

5
SDLP / Seadrill Partners LLC / Seadrill Ltd - SCHEDULE 13D/A (Activist Investment)

2018-07-10 sec.gov
SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SDLP

6
SDLP / Seadrill Partners LLC / Seadrill Ltd - SCHEDULE 13D/A (Activist Investment)

2018-07-10 sec.gov
SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SDLP

6
Rowan Companies stock price target raised to $20 from $16 at B. Riley FBR

2018-06-11 marketwatch
B.Riley FBR analyst Tom Curran maintained a Buy rating on Rowan Companies (NYSE: RDC) yesterday ...[...]
SDLP RDC CQP LNG

100
Jack-Up Competition Intensifies

2018-06-04 seekingalpha
I wrote about the newbuild overhang in the jack-up market back in March. Now these rigs may slowly start getting to market.
SDLP NE PGNPQ NOBGF HERO ESV PACDQ N21 NOBGY SDRL BDRLF RIG HEROQ

1
Diving into Seadrill Partners’ Q1 2018 Results

2018-05-31 marketrealist
Seadrill Partners (SDLP) released its results for the first quarter of 2018 on May 25. Its stock hasn’t had a good run YTD (year-to-date), falling more than 11% during the period.
SDLP

2
Seadrill Stock Fell 32% in Week 21

2018-05-30 marketrealist
After a fantastic run for Seadrill (SDRL) in week 20, the stock fell in the following week. In week 20, Seadrill reached a 52-week high of $0.73. The stock rose more than 98% in week 20. This situation turned around in week 21 (week ending May 25) and the stock fell more than 32%. We already mentioned in our previous article that the stock rise was not based on fundamentals. Also, Seadrill’s technicals suggested the stock was overbought and overvalued.
SDLP RDC

100
SDLP / Seadrill Partners LLC - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-30 fintel.io
Seadrill Partners LLC (NYSE:SDLP) has 53 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 37,243,183 shares. Largest shareholders include Seadrill Ltd, Strategic Value Partners, LLC, Prescott Group Capital Management, L.l.c., Morgan Stanley, Q Global Advisors, LLC, Babson Capital Management Llc, Acadian Asset Management Llc, California Public Employees Retirement System, HighTower Advisors, LLC, and Deutsche Bank Ag\.
SDLP DB MS.PRI MS.PRK MS.PRE SDRL FH MS.PRF MS.PRG MS MS.PRA XSPA

2
SDLP / Seadrill Partners LLC / SEADRILL LTD - SCHEDULE 13D/A (Activist Investment)

2018-05-30 sec.gov
SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SDLP

8
SDLP / Seadrill Partners LLC / SEADRILL LTD - SCHEDULE 13D/A (Activist Investment)

2018-05-30 sec.gov
SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SDLP

105
Top MLP Losses in the Week Ending May 25

2018-05-29 marketrealist
Legacy Reserves (LGCY), the upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) production, was the top MLP loss last week. Legacy Reserves fell 36.2% mainly due to the weakness in crude oil prices. Although Legacy Reserves has fallen significantly from its YTD highs, it’s still up 217.4% in 2018. The stock might continue to see high volatility in the near term due to strong movements in crude oil prices.
CCLP LGCYP SDLP LGCYO AMID LGCY SDRL SXE PAA BPL HCLP SNMP

77
Seadrill Partners - A Struggling Recovery

2018-05-27 seekingalpha
The backlog remaining is $1.3 billion extending until 2020. I have estimated about $434 million in backlog in 2018.
SDLP SDRL

1
Seadrill Partners: Q1 2018 Earnings Results Analysis

2018-05-25 seekingalpha
The main reason for this is that the company had fewer rigs working and a high amount of planned downtime on another rig.
SDLP

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: Y7545W109